comparemela.com

Latest Breaking News On - Ytosorbents aktie - Page 1 : comparemela.com

Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb Intraoperatively in Heart Transplant Patients

17.01.2024 - CytoSorb Blood Purification Results in Statistically Significant Reductions in Multiple Organ Failure and DysfunctionPRINCETON, N.J., Jan. 17, 2024 (GLOBE NEWSWIRE) - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of . Seite 1

Adam solteszEuropean society of cardiologyVascular center at semmelweis universityCytosorbents corporationCytosorb blood purification resultsStatistically significant reductionsMultiple organ failureSorbents corporationEuropean societyVascular centerSemmelweis universityVasoactive inotropic scoresVasoplegic syndromeCytosorbents chartYtosorbents kursYtosorbents aktie

CytoSorbents to Report Third Quarter 2023 Operating and Financial Results

27.10.2023 - PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter . Seite 1

New yorkUnited statesParticipant dial inInvestor relationsCytosorbents chartYtosorbents kursYtosorbents aktie

CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry Seite 1

27.09.2023 - PRINCETON, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer . Seite 1

Brilinta briliqueSavaysa lixianaInternational safeTimely antithrombotic removalCytosorbents chartYtosorbents kursYtosorbents aktie

vimarsana © 2020. All Rights Reserved.